Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity
- PMID: 31285395
- PMCID: PMC6697124
- DOI: 10.1542/peds.2018-2690
Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity
Abstract
Background and objectives: Adolescents represent the largest age group that presents to emergency departments (ED) for synthetic cannabinoid (SC) toxicity; however, the neurotoxic effects of acute SC exposures in this group are understudied. Our aim was to characterize the neuropsychiatric presentation of adolescents with SC-related exposure in the ED compared with those with traditional cannabis exposure.
Methods: A multicenter registry of clinical information prospectively collected by medical toxicologists (Toxicology Investigators Consortium Case Registry) was reviewed for adolescents presenting to the ED after SC or cannabis exposure from 2010 through 2018. Associations were measured between drug exposures and neuropsychiatric symptoms and/or signs. Exposures were classified into 4 groups: SC-only exposure, SC-polydrug exposures, cannabis-only exposure, and cannabis-polydrug exposures.
Results: Adolescents presenting to the ED with SC-only exposure (n = 107) had higher odds of coma and/or central nervous system depression (odds ratio [OR] 3.42; 95% confidence interval [CI] 1.51-7.75) and seizures (OR 3.89; 95% CI 1.39-10.94) than those with cannabis-only exposure (n = 86). SC-only drug exposure was associated with lower odds of agitation than cannabis-only exposure (OR 0.18; 95% CI 0.10-0.34). In contrast, the group with SC-polydrug exposures (n = 38) had higher odds of agitation (OR 3.11; 95% CI 1.56-7.44) and seizures (OR 4.8; 95% CI 1.80-12.74) than the cannabis-polydrug exposures group (n = 117).
Conclusions: In this multisite cohort of US adolescents assessed in the ED, SC exposure was associated with higher odds of neuropsychiatric morbidity than cannabis exposure providing a distinct neurospychiatric profile of acute SC toxicity in adolescents.
Copyright © 2019 by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Similar articles
-
Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.Clin Toxicol (Phila). 2024 Jun;62(6):378-384. doi: 10.1080/15563650.2024.2346125. Epub 2024 Jun 27. Clin Toxicol (Phila). 2024. PMID: 38934347
-
Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.Psychopharmacology (Berl). 2019 Sep;236(9):2677-2685. doi: 10.1007/s00213-019-05238-8. Epub 2019 Apr 9. Psychopharmacology (Berl). 2019. PMID: 30968175 Free PMC article.
-
Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States.Drug Alcohol Depend. 2020 Feb 1;207:107810. doi: 10.1016/j.drugalcdep.2019.107810. Epub 2019 Dec 16. Drug Alcohol Depend. 2020. PMID: 31862557 Free PMC article.
-
The Psychiatric Consequences of Cannabinoids.Clin Ther. 2018 Sep;40(9):1448-1456. doi: 10.1016/j.clinthera.2018.03.013. Epub 2018 Apr 17. Clin Ther. 2018. PMID: 29678279 Review.
-
Cannabis use disorder: epidemiology and management.Int Rev Psychiatry. 2009 Apr;21(2):96-103. doi: 10.1080/09540260902782745. Int Rev Psychiatry. 2009. PMID: 19367503 Review.
Cited by
-
Synthetic Marijuana: Assessment of Usage, Motivation and Associated Risks in Adolescent Substance Users.Subst Use. 2024 May 17;18:29768357241254258. doi: 10.1177/29768357241254258. eCollection 2024 Jan-Dec. Subst Use. 2024. PMID: 38764525 Free PMC article.
-
Reduced fetal cerebral blood flow predicts perinatal mortality in a mouse model of prenatal alcohol and cannabinoid exposure.BMC Pregnancy Childbirth. 2024 Apr 11;24(1):263. doi: 10.1186/s12884-024-06436-9. BMC Pregnancy Childbirth. 2024. PMID: 38605299 Free PMC article.
-
Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents.Br J Psychiatry. 2023 Oct;223(4):478-484. doi: 10.1192/bjp.2023.91. Br J Psychiatry. 2023. PMID: 37485911 Free PMC article.
-
Synthetic cannabinoid-associated acute interstitial nephritis: An emerging cause of pediatric acute kidney injury?Clin Nephrol Case Stud. 2023 Mar 27;11:55-60. doi: 10.5414/CNCS111063. eCollection 2023. Clin Nephrol Case Stud. 2023. PMID: 37006641 Free PMC article.
-
Correction to: The Potential Proconvulsant Effects of Cannabis: a Scoping Review.J Med Toxicol. 2023 Jan;19(1):54-60. doi: 10.1007/s13181-022-00915-1. J Med Toxicol. 2023. PMID: 36322377 Free PMC article. No abstract available.
References
-
- Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373(2): 103–107 - PubMed
-
- United Nations Office on Drugs and Crime. Synthetic cannabinoids in herbal products: United Nations Document ID: SCITEC/24. Available at: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf. Accessed May 21, 2019
-
- United Nations Office on Drugs and Crime. Recommended methods for identification and analysis for synthetic cannabinoid receptor agonists in seized materials. 2013. UN document ID: ST/NAR/48. Available at: http://www.unodc.org/documents/scientific/STNAR48_Synthetic_Cannabinoids.... Accessed May 21, 2019 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
